How is it applied?
It is recommended for both dry and wet hair and is applied from the mid-lengths to the ends, especially in the most damaged areas.
What is CBD and why is it safe?
CBD is one of over a hundred "phytocannabinoids" that can be found exclusively in cannabis and that give the plant a highly therapeutic profile.
Similarly, it is safe because the World Health Organization, the UN and other institutions have already officially recognised the benefits of CBD. It is not an addictive substance, nor does it cause anxiety, paranoia, hallucinations or anxiety. This is because this substance does not contain tetrahydrocannabinol (THC), the psychoactive ingredient found in marijuana that produces these effects.
Is CBD legal?
Yes! In many countries around the world, such as the US, the UK and Canada, it is legal and its most widespread and recommended use is by applying a few drops under the tongue. However, in Spain only its topical use is regulated.
Does it have side effects?
It has no side effects in its topical use (except those allergic reactions that it could cause like any other product).
What does the WHO say about cannabidiol (CBD)?
About cannabidiol preparations. At its 40th meeting, the Expert Committee on Drug Dependence considered a critical review of cannabidiol and recommended that preparations considered to be pure cannabidiol should not be listed in the international drug control treaties.
Although cannabidiol is present in cannabis and cannabis resin, it does not have psychoactive properties or the potential to cause addiction and dependence. It also does not cause significant harmful effects.
Cannabidiol has been shown to effectively treat certain childhood-onset seizure disorders that do not respond to other treatments. It was approved for this indication in the United States of America in 2018, and the EU is currently considering authorising it.
Cannabidiol can be obtained through chemical synthesis or from the cannabis plant. The authorised medicine (Epidiolex) is a preparation of the cannabis plant.
The Committee noted that drugs which do not have psychoactive effects and which are manufactured as preparations from the cannabis plant contain trace amounts of delta-9-tetrahydrocannabinol (Δ9 -THC; dronabinol). Epidiolex, which is the cannabidiol preparation licensed to treat childhood-onset epilepsy, contains a maximum of 0.15 percent Δ9 -THC by weight and does not cause effects suggestive of misuse or dependence. In accordance with the recommendation that preparations that are considered pure cannabidiol not be subject to control, recognising the concentration of traces of Δ9 -THC that such preparations may contain (such as the 0.15 percent present in Epidiolex), and taking Note that some Member States may find it difficult to perform chemical analyzes that can accurately detect 0.15 percent concentrations of Δ 9 -THC:
Recommendation 5.5: The Committee recommended adding a footnote to Schedule I of the 1961 Single Convention on Narcotic Drugs stating: "Preparations containing predominantly cannabidiol and not more than 0.2 percent delta -9-tetrahydrocannabinol are not subject to international control."
(Verbatim citation Extract from the Report of the 41st Expert Committee on Drug Dependence, section 5.5 entitled cannabis and cannabis-related substances).